Reperfusion injury – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:09 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Reperfusion injury – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Sodium Lactate and Electrolyte Solution in Comatose Patients After Cardiac Arrest https://clinicaltrials.eu/trial/study-on-the-effects-of-sodium-lactate-and-electrolyte-solution-in-comatose-patients-after-cardiac-arrest/ Wed, 29 Apr 2026 14:59:35 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-sodium-lactate-and-electrolyte-solution-in-comatose-patients-after-cardiac-arrest/ This clinical trial is focused on studying the effects of a treatment for patients who have experienced a cardiac arrest, which is when the heart suddenly stops beating. After such an event, patients may suffer from post-anoxic brain injury, a type of brain damage that occurs due to a lack of oxygen, and may fall into a coma. The trial aims to evaluate the effectiveness of a treatment using a solution called SODIO LATTATO MONICO, which contains sodium lactate, to help reduce brain injury in patients who are comatose after cardiac arrest.

The study will involve administering the treatment through an intravenous infusion, which means the solution is given directly into a vein. Another solution, Plasmalyte A Viaflo, which contains a mix of electrolytes like magnesium chloride hexahydrate, potassium chloride, sodium chloride, sodium acetate trihydrate, and sodium gluconate, may also be used. The purpose of the study is to see if these treatments can help improve outcomes for patients by decreasing the extent of brain injury after a cardiac arrest.

Participants in the study will receive the treatment for a short period, and their progress will be monitored over time. The study will look at various outcomes, such as the level of certain proteins in the blood that indicate brain injury, the patient’s recovery in terms of brain function, and their overall health status during their stay in the hospital. The goal is to gather information that could lead to better treatments for people who have suffered a cardiac arrest and are in a coma.

]]> Study on Alkaline Phosphatase for Reducing Kidney Transplant Complications in Patients with End-Stage Kidney Disease https://clinicaltrials.eu/trial/study-on-alkaline-phosphatase-for-reducing-kidney-transplant-complications-in-patients-with-end-stage-kidney-disease/ Wed, 29 Apr 2026 14:58:20 +0000 https://clinicaltrials.eu/trial/study-on-alkaline-phosphatase-for-reducing-kidney-transplant-complications-in-patients-with-end-stage-kidney-disease/ This clinical trial is focused on studying a condition known as ischemia reperfusion injury, which can occur during kidney transplantation. This condition can lead to a complication called delayed graft function, where the transplanted kidney does not work immediately and the patient may need dialysis within the first week after the transplant. The trial is investigating whether a treatment using a substance called alkaline phosphatase, bovine, marketed under the name bRESCAP, can help prevent this injury and reduce the duration of delayed graft function.

Participants in the study will receive either the treatment with bRESCAP or a placebo, which is a substance with no active medication. The treatment is given as an IV infusion, which means it is administered directly into a vein. The study aims to see if the treatment can decrease the need for dialysis and improve kidney function after transplantation. The trial will also monitor other factors such as the length of hospital stay, kidney function over time, and any potential rejection of the transplanted kidney.

The study will follow participants for up to a year to gather comprehensive data on the effectiveness of the treatment. This includes measuring kidney function through tests like creatinine clearance and estimated glomerular filtration rate (eGFR), as well as checking for any signs of kidney rejection or other complications. The ultimate goal is to improve outcomes for patients receiving kidney transplants from donors who have experienced circulatory death.

]]>